Late-onset cardiotoxicity of chemotherapy and radiotherapy

Netherlands Journal of Medicine

Volumn 61, Issue 6, 2003, Pages 228-231

  Dietz, B ^a   van der Hem, K G ^a  

^a ZAANS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLEOMYCIN; CARMUSTINE; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXORUBICIN; ETOPOSIDE; GLYCERYL TRINITRATE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE; ANTINEOPLASTIC AGENT;

ADULT; ANAPLASTIC CARCINOMA; ANGINA PECTORIS; AORTA VALVE REGURGITATION; AORTA VALVE REPLACEMENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CASE REPORT; CIGARETTE SMOKING; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DYSPNEA; EARLY MENOPAUSE; ECHOCARDIOGRAPHY; EDEMA; ENDOCARDITIS; FEMALE; FOLLOW UP; HEART DISEASE; HEART INJURY; HEART MURMUR; HEART PALPITATION; HEART VENTRICLE TACHYCARDIA; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHYROIDISM; LARGE CELL LYMPHOMA; MITRAL VALVE REGURGITATION; PERICARDIAL EFFUSION; PERICARDITIS; RISK FACTOR; RISK REDUCTION; SINUS TACHYCARDIA; ST SEGMENT DEPRESSION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT INDICATION; LYMPHOMA; RADIOTHERAPY;

ADULT; ANTINEOPLASTIC AGENTS; FEMALE; HEART DISEASES; HUMANS; LYMPHOMA; RADIOTHERAPY;

EID: 0141797512     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Ossenkoppele GJ, Schuurhuis GJ, Jonkhoff AR, et al. G-CSF (filgrastim)-stimulated whole blood kept unprocessed at 4 degrees C does support a BEAM-like regimen in bad-risk lymphoma. Bone Marrow Transpl 1996;18:427-31.
2. Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol 1993;11:1208.
3. Hoff DD von, Layard MW, Baso P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-7.
4. Shan K, Lincoff M, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996;125:47-58.
5. Keefe DL. Anthracycline-induced cardiomyopathy. Semin Oncol 2001;28:2-7.
6. Minotti G, Cairo G, Monti E. Role of iron in anthracycline cardiotoxicity: new tune for an old song? FASEB J 1999;13:199-212.
7. Steinherz LJ, Steinherz PG, Tan CTC, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266:1672-7.
8. Zambetti M, Moliterni A, Materazzo C, et al. Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J Clin Oncol 2001;19:37-43.
9. Jain D. Cardiotoxicity of doxorubicin and other anthracycline derivatives. J Nucl Cardiol 2000;7:53-62.
10. Bielack SS, Erttmann R, Kempf-Bielack B, Winkler K. Impact of scheduling and clinical efficacy of doxorubicin: what do we know in the mid-nineties? Eur J Cancer 1996;32A:1652-60.
11. Lund MB, Ihlen H, Voss MR, et al. Increased risk of heart valve regurgitation after mediastinal radiation for Hodgkin's disease: an echocardiographic study. Heart 1996;76:591-5.
12. Paglia DE, Radcliffe RW. Anthracycline cardiotoxicity in a black rhinoceros (Diceros bicornis): evidence for impaired antioxidant capacity compounded by iron overload. Vet Pathol 2000;37:86-8.
13. Hershko C, Pinson A, Link C. Prevention of anthracycline cardiotoxicity by iron chelation. Acta Hematol 1996;95:87-92.
14. Meinardi MT, Graaf WT van der, Veldhuizen DJ van, Gietema JA, Vries EG de, Sleijfer DT. Detection of anthracycline-induced cardiotoxicity. Cancer Treat Rev 1999;25:237-47.
15. Schwartz RG, McKenzie WB, Alexander J, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven year experience using serial radionuclide angiocardiography. Am J Med 1987;82:1109.
16. Choi BW, Berger HJ, Schwartz PE, et al. Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance. Am Heart J 1983;106:638-43.
17. Zalewsky-Szewczyk B, Lipiec J, Bodalski J. Late cardiotoxicity of anthracyclines in children with acute leukemia. Klin Pediatr 1999;211:356-9.
18. Dreicer R, Karwal MW, Midence G, Davis CS, Nettleman M. The role of radionuclide angiocardiography in the treatment of patients receiving doxorubicin-based chemotherapy: a reassessment. Am J Clin Oncol 1997;20:132-7.
19. Nysom K, Holm K, Lipsitz SR, et al. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol 1998;16:545-50.
20. Shureiqi I, Cantor SB, Lippman SM, Brenner DE, Chernev ME, Fendrick AM. Clinical and economic impact of multiple gated acquisition scan monitoring during anthracycline therapy. Br J Cancer 2002;86:226-32.
21. Johnson GL, Moffett CB, Geil JD, Greenwood MF, Noonan JA. Late echocardiographic findings following childhood chemotherapy with normal serial cardiac monitoring. J Pediat Hematol Oncol 1996;18:72-5.
22. Nousiainen T, Vanninen E, Jantunen E, et al. Comparison of echocardiography and adionuclide ventriculography in the follow-up of left ventricular systolic function in adult lymphoma patients during doxorubicin therapy. J Intern Med 2001;249:297-303.
23. Nousiainen T, Jantunen E, Vanninen E, Hartikainen J. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer 2002;86:1697-700.
24. Wassmuth R, Lentzsch S, Erdbruegger U, et al. Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging- a pilot study. Am Heart J 2001;141:1007-13.
25. Seymour L, Bramwell V, Moran LA. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. Cancer Prev Control 1999;3:145-59.
26. Wiseman LR, Spencer CM. Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Drugs 1998;56:385-403.
27. Kakavas PW, Ghalie R, Parrillo JE, Kaizer H, Barron JT. Angiotensin converting enzyme inhibitors in bone marrow transplant recipients with depressed left ventricular function. Bone Marrow Transplant 1995;15:859-61.
28. Musci M, Loebe M, Grauhan O, et al. Heart transplantation for doxorubicin-induced congestive heart failure in children and adolescents. Transplant Proc 1997;29:578-9.
29. Levitt G, Bunch K, Rogers CA, Whitehead B. Cardiac transplantation in childhood cancer survivors in Great Britain. Eur J Cancer 1996;32A:826-30.
30. Benoff LJ, Schweitzer P. Radiation therapy-induced cardiac injury. Am Heart J 1995;129:1193-9.
31. Hancock S, Tucker M, Hoppe R. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993;270:1949-55.
32. Hancock SL, Hoppe RT. Long-term complications of treatment and causes of mortality after Hodgkin's disease. Semin Radiat Oncol 1996;6:225-42.
33. Lund MB, Kongerud J, Boe J, et al. Cardiopulmonary sequelae after treatment for Hodgkin's disease: Increased risk in females? Ann Oncology 1996;7:257-64.
34. Brosius FC, Walter BF, Roberts WG. Radiation heart disease: analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart. Am J Med 1981;70:519-30.